ストックスクリーナーアプリを入手
0.1838
0.27%
0.0005
アフターアワーズ：
.18
-0.0038
-2.07%
前日終値:
$0.1833
開ける：
$0.19
24時間の取引高:
2.22M
Relative Volume:
1.16
時価総額：
$18.03M
収益：
$190.00K
当期純損益:
$-70.03M
株価収益率:
-0.2503
EPS:
-0.7343
ネットキャッシュフロー:
$-59.30M
1週間 パフォーマンス:
-28.01%
1か月 パフォーマンス:
-52.77%
6か月 パフォーマンス:
-78.19%
1年 パフォーマンス:
-81.98%
1日の値動き範囲:
$0.1838
$0.197
1週間の範囲:
$0.1807
$0.2591
52週間の値動き範囲:
$0.1807
$1.11
Atyr Pharma Inc Stock (ATYR) Company Profile
名前
Atyr Pharma Inc
セクター
電話
(858) 731-8389
住所
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.1838 | 18.03M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-16 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | 開始されました | Leerink Partners | Outperform |
| 2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 開始されました | Wells Fargo | Overweight |
| 2024-09-05 | 開始されました | Jefferies | Buy |
| 2023-07-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-09-21 | 開始されました | Piper Sandler | Overweight |
| 2021-05-10 | 開始されました | Laidlaw | Buy |
| 2020-08-17 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 開始されました | ROTH Capital | Buy |
| 2020-03-02 | 開始されました | Oppenheimer | Outperform |
| 2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 開始されました | Piper Jaffray | Overweight |
| 2016-12-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 開始されました | Citigroup | Neutral |
| 2015-06-01 | 開始されました | Citigroup | Buy |
| 2015-06-01 | 開始されました | JP Morgan | Overweight |
すべてを表示
Atyr Pharma Inc (ATYR) 最新ニュース
A trust and three trustees report a passive stake above 5% in aTyr Pharma (ATYR). - Stock Titan
aTyr Pharma stock faces October 16 reverse split vote - AD HOC NEWS
The CFO receives options on 410,000 shares with a $0.30 exercise price at aTyr Pharma (ATYR). - Stock Titan
aTyr Pharma (Nasdaq:ATYR)Stock Analysis - Simply Wall Street
aTyr Pharma, Inc. Statistics – HAN:471A - TradingView
Ethos Technologies Inc. Class A Common Stock (NASDAQ: LIFE) Stock Price, News & Analysis - Kalkine
aTyr Pharma (NASDAQ: ATYR) Schedules October 16 Vote on Reverse Stock Split Between 1-for-10 and 1-for-50 - Kalkine Media
BioMarin (NASDAQ: BMRN) director awarded 6,140 stock units - Stock Titan
Insider buys 12.5M warrants in Hepion Pharmaceuticals (HEPA) that need shareholder approval - stocktitan.net
ANI Pharmaceuticals (NASDAQ: ANIP) director plans $71K share sale - Stock Titan
Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight - Yahoo Finance
aTyr Pharma (ATYR) Holds at $0.50 as Mild Buying Interest Supports Biotech Micro-CapThrowback Trade - siam.in
aTyr Pharma Provides Update on FDA Response Timing for Planned Phase 3 Efzofitimod Sarcoidosis Study - Quiver Quantitative
Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis - TradingView
aTyr Pharma Provides Update on Timing of Regulatory - GlobeNewswire
FDA response expected by mid-September for aTyr’s lung disease trial - Stock Titan
Nasdaq starts delisting Crinetics (NASDAQ: CRNX) shares and ends its Section 12(b) listing - Stock Titan
aTyr Pharma Inc. (LIFE) Peer Comparison – Compare with Others - Value Research
aTyr Pharma Inc. (LIFE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - Sahm
aTyr Pharma And 2 Other Penny Stocks With Promising Potential - simplywall.st
aTyr (ATYR) Snapshot: Falls 0.20% to $0.50 on the Day; Immediate View: Price Remains Between $0.47 Support and $0.53 Resistance in the Latest SessionPrice Momentum Stocks - vinanet.vn
aTyr (ATYR) Snapshot: Falls 0.20% to $0.50 on the Day; Immediate View: Price Remains Between $0.47 Support and $0.53 Resistance in the Latest SessionSingle Stock ETF - siam.in
FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III - Freedom Broker
FB: aTyr Pharma shares have over 500% upside as the company prepares a new Phase III - Freedom Broker
aTyr Pharma Company Profile & Introduction - Moomoo
ATYR Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesFree Cash Flow Trends - vinanet.vn
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright - MarketBeat
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Why is aTyr Pharma stock gaining today? By Investing.com - Investing.com India
Why is aTyr Pharma stock gaining today? By Investing.com - Investing.com Canada
H.C. Wainwright Maintains ATyr Pharma(ATYR.US) With Hold Rating - moomoo.com
Why is aTyr Pharma stock gaining today? - Investing.com
Levi & Korsinsky Urges aTyr (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - The National Law Review
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - The National Law Review
ATyr Pharma Announces Second Quarter 2026 Res - Moomoo
aTyr Pharma Q2 Results: EPS of $(0.11) beats estimates - scanx.trade
ATYR Looks 13.6% Overvalued on GF Value™ as Cash Supports Develo - GuruFocus
ATYR Looks 13.6% Overvalued on GF Value™ as It Restructures Amid Pulmonary Sarcoidosis Focus - GuruFocus
ATyr Pharma Sees Funding Sufficient Into Late 2028 >ATYR - moomoo.com
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky - The National Law Review
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR) – Join by December 8, 2025 – Contact Levi & Korsinsky - The National Law Review
ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - marketscreener.com
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans - Moomoo
ATyr Pharma Fiscal Q2 Loss Narrows - marketscreener.com
aTyr Pharma cuts 60% of workforce after Q2 results - Quiver Quantitative
Atyr Pharma: Q2 Earnings Snapshot - Barchart.com
aTyr Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
aTyr Pharma Q2 net loss narrows - TradingView
Atyr Pharma Inc (ATYR) 財務データ
収益
当期純利益
現金流量
EPS
Atyr Pharma Inc (ATYR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Shukla Sanjay | President and CEO |
Feb 04 '26 |
Sale |
0.98 |
3,745 |
3,655 |
153,553 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
1.35%
大文字化:
|
ボリューム (24 時間):